NASDAQ:KPTI

Karyopharm Therapeutics Stock News

Healthcare > Biotechnology

Buy KPTI

*Your capital is at risk

$9.00

-0.230 (-2.49%)

At Close: Jun 03, 2026

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

08:00pm, Monday, 05'th Jul 2021

SHANGHAI and HONG KONG, July 5, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and

Karyopharm Announces Expansion Of Royalty Agreement With Healthcare Royalty For Up To $100 Million

07:00am, Thursday, 24'th Jun 2021

NEWTON, Mass., June 24, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the expansion of i

Karyopharm: Why Is It Down, And What Should Take It Back Up

01:56pm, Wednesday, 23'rd Jun 2021

I list 8 potential reasons the stock is down despite approvals. SIENDO is a major binary event for the stock.

Karyopharm Stock Is Trading Higher On Updated Eltanexor Data In Patients With Blood Disorder

01:49pm, Wednesday, 09'th Jun 2021

Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced updated data from Phase 1/2 trial of eltanexor (ATG-016) for patients with hypomethylating agent (HMA) refractory myelodysplastic syndrome (MDS)

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress

07:00am, Wednesday, 09'th Jun 2021

NEWTON, Mass., June 9, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that nine abstrac

Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS

08:00pm, Tuesday, 08'th Jun 2021

--Of the 15 patients evaluable for efficacy, 7 (47%) had mCR and 5 (33%) had SD for a total disease control rate of 80%-- --Patients with mCR had longer mOS than patients without mCR or with PD-- SHAN

Karyopharm Announces Key Changes to Its Commercial Leadership Team

04:01pm, Tuesday, 08'th Jun 2021

NEWTON, Mass., June 8, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced key management ch

Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

07:00am, Wednesday, 02'nd Jun 2021

NEWTON, Mass., June 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that on May 26, 20

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting

05:01pm, Wednesday, 19'th May 2021

NEWTON, Mass., May 19, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that sixteen abstr

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

02:52pm, Sunday, 16'th May 2021

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

08:00pm, Wednesday, 12'th May 2021

SHANGHAI and HONG KONG, May 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by